Form 8-K

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 30, 2012

 

 

AVEO Pharmaceuticals, Inc.

(Exact Name of Registrant as Specified in Charter)

 

 

 

Delaware   001-34655   04-3581650

(State or Other Jurisdiction

of Incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

75 Sidney Street

Cambridge, Massachusetts

  02139
(Address of Principal Executive Offices)   (Zip Code)

Registrant’s telephone number, including area code: (617) 299-5000

 

(Former Name or Former Address, if Changed Since Last Report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 


Item 5.07 Submission of Matters to a Vote of Security Holders.

At the annual meeting of shareholders of AVEO Pharmaceuticals, Inc. (the “Company”) held on May 30, 2012, the Company’s shareholders voted on the following proposals:

1. The following nominees were elected to the Company’s Board of Directors for terms expiring at the 2013 annual meeting of shareholders.

 

     For      Withheld      Broker Non-Votes  

Mr. Kenneth Bate

     33,585,100         150,035         4,356,839   

Dr. Ronald DePinho

     33,623,051         112,084         4,356,839   

Dr. Anthony Evnin

     33,708,223         26,912         4,356,839   

Mr. Tuan Ha-Ngoc

     33,670,381         64,754         4,356,839   

Dr. Raju Kucherlapati

     33,662,626         72,509         4,356,839   

Mr. Henri Termeer

     33,579,070         156,065         4,356,839   

Mr. Kenneth Weg

     19,084,041         14,651,094         4,356,839   

Dr. Robert Young

     33,707,123         28,012         4,356,839   

2. A non-binding, advisory proposal on the compensation of the Company’s named executive officers was approved.

 

For:

     33,471,047   

Against:

     256,138   

Abstain:

     7,950   

Broker Non-Votes:

     4,356,839   

3. The appointment of Ernst & Young LLP as the independent registered public accounting firm for the Company for the fiscal year ending December 31, 2012 was ratified.

 

For:

     37,919,378   

Against:

     160,724   

Abstain:

     11,872   


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    AVEO Pharmaceuticals, Inc.
Date: June 4, 2012     By:  

/s/ David B. Johnston

     

David B. Johnston

Chief Financial Officer